Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (131-140 of 205) with videos related to

Pageof 21
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET InhibitorIbiayi Dagogo-Jack, Philicia Moonsamy, Justin F Gainor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerJustin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.
Cancer Discovery|March 28, 2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerJim Sang, Jaime Acquaviva, Julie C Friedland, et al.
The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung CancerCaroline E McCoach, Collin M Blakely, Kimberly C Banks, et al.
Future Oncology (London, England)|October 3, 2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancerBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i>-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN StudyBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.
The Lancet. Oncology|December 29, 2015
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialAlice T Shaw, Leena Gandhi, Shirish Gadgeel, et al.
Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Pageof 21

Showing results (131-140 of 205) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET InhibitorIbiayi Dagogo-Jack, Philicia Moonsamy, Justin F Gainor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerJustin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.
Cancer Discovery|March 28, 2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerJim Sang, Jaime Acquaviva, Julie C Friedland, et al.
The Lancet. Respiratory Medicine|December 19, 2022
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung CancerCaroline E McCoach, Collin M Blakely, Kimberly C Banks, et al.
Future Oncology (London, England)|October 3, 2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancerBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i>-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN StudyBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.
The Lancet. Oncology|December 29, 2015
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialAlice T Shaw, Leena Gandhi, Shirish Gadgeel, et al.
Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Pageof 21